Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis

Respiratory Failure Clinical Trial

— RSV-SAM  

Official title:

Validation of Nasal and Bronchial Absorption Sampling Methods for the Assessment of RSV Bronchiolitis in Babies and Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03062917
• Other study ID #: 15/WM/0343
• Status: Completed
• Phase: N/A
• Start date: October 2, 2015
• Est. completion date: June 30, 2018

Study information

• Verified date: October 2019
• Source: Imperial College Healthcare NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will compare the novel methods of NS and BS with the standard technique of nasophayngeal aspiration (NPA) and routine ETT suction. We shall assess the samples for diagnosis of RSV, viral load and immune responses in the airways of babies with RSV infection. We shall also assess the genetics of babies included in this study, to see if they may be vulnerable to RSV infection.

Description:

In conjunction with a specialist medical device manufacturing company (Hunt Developments (Midhurst, West Sussex) we have produced novel nasosorption and bronchosorption kits that have CE marking. Both nasosorption and bronchosorption methods use synthetic absorptive matrix (SAM) strips: that look and feel like blotting paper, and will be placed onto the mucosal surface. These are comfortable to use and can be used at frequent intervals over extended periods of time. This non-invasive technique is ideal for infants and children, and it is possible to obtain neat mucosal lining fluid (MLF) even from normal healthy noses. The eluates contain cytokines and chemokines at high detectable levels on multiplex immunoassay.

We would like to use these SAMs to take MLF samples from the nasal and bronchial mucosal surfaces to see if these novel techniques can overcome the problems with current sampling methods. We plan to use these absorption techniques to measure RSV viral load. We also aim to look at the immune response in terms of the anti-viral interferon response (IFN-γ, IFN-λ, IFN-α2a, IP10, ITAC). In therapeutic studies in the future, it may be possible to document levels of drug (pharmacokinetics) in nasal MLF.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 152
• Est. completion date: June 30, 2018
• Est. primary completion date: June 30, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 2 Years

Eligibility

Group 1 and Group 2

Inclusion Criteria

• Infants aged 2 weeks-24 months

• Presentation to the Emergency Department with any upper respiratory tract infection (URTI) in the RSV season (Oct-March).

OR • Documented RSV infection, admitted to the paediatric wards at St Mary's Hospital.

Exclusion Criteria

• Any local or systemic factor that would influence the safety of nasal sampling.

• Bilateral indwelling nasal catheters or local nasal pathology preventing access for nasal sampling.

• Bleeding disorders.

• The baby is taking part in another interventional study.

• The parents or guardians not able to sign the informed consent from due to limited English or comprehension despite the use of independent interpreter services.

• Limited life expectancy of the baby,

Group 3

Inclusion criteria

• Hospitalised Infants admitted to the PICU at St. Mary's Hospital, aged 2 weeks-24 months with documented RSV infection (by rapid test and/or PCR).

• Infants of weight >2kg.

• On a conventional ventilator with an Endotracheal Tube (ETT) of >3.0mmm diameter

Exclusion criteria

• Any local or systemic factor that would influence the safety of nasal sampling.

• Bilateral nasal catheters or local nasal pathology preventing access for nasal sampling.

• The baby is taking part in another interventional study.

• Prematurity - corrected gestational age <36 weeks, weight <2kg

• Significant hypoxia or instability precluding ventilator disconnection

• ETT < 3mm internal diameter

• Transcutaneous oxygen saturation of <95% on 60% oxygen

• Risk of bleeding

• Pneumothorax

• Infants receiving oral corticosteroid therapy at any time in past month

• Parents or guardians not able to sign informed consent from due to limited English or understanding despite the use of independent interpreter services.

• Limited life expectancy or a decision to limit management,

Control Group 1 Inclusion criteria

• Babies, aged 2 weeks-24 months, attending routine outpatient appointments or undergoing elective surgical procedures.

Exclusion criteria

• Any respiratory symptoms

• All other exclusion are the same as Groups 1 and 2

Control Group 2

Inclusion criteria

• Infants aged 2 weeks-24 months.

• Infants ventilated on the PICU for any condition

• Confirmed RSV negative by PCR of respiratory tract samples

Exclusion Criteria

• All exclusions are the same as Group 3

• In addition - any concern about raised intracranial pressure

Related Conditions & MeSH terms

• Bronchiolitis
• Bronchiolitis, Viral
• Respiratory Failure
• Respiratory Insufficiency
• Respiratory Syncytial Virus Infections
• RSV Infection

Intervention

Diagnostic Test:
• Nasal and Bronchial Sampling
Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.

Locations

Country	Name	City	State
United Kingdom	Imperial College NHS Healthcare Trust	London

Sponsors (2)

Lead Sponsor	Collaborator
Imperial College Healthcare NHS Trust	Pulmocide Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling	To determine the difference in tolerability of nasosorption compared to NPA by assessment of acceptance by infants and families. Samples were collected from participants up to twice daily throughout study involvement, as such each participant could have >1 sampling visits.	Throughout symptomatic respiratory infection, up to 1 month
Primary	Accuracy of Nasosorption for Viral Load Measurement	To determine the difference in accuracy of nasosorption compared to NPA by assessment of level of viral load (measured by qPCR).	Throughout symptomatic respiratory infection, up to 1 month
Primary	Accuracy of Bronchosorption for Viral Load Measurement, Compared to Tracheal Aspirate	To determine the difference in accuracy of bronchosorption (BSAM) compared to tracheal aspirate (TA) by assessment of level of viral load (measured by qPCR).	Throughout symptomatic respiratory infection, up to 1 month
Secondary	Immune Response	Establishing the use of nasal and bronchial sampling to measure the host immune response to RSV. We will determine cytokine and inflammatory mediator concentrations by immunoassay of eluted fluid from nasosorption and compare with NPA.	Throughout symptomatic respiratory infection, up to 1 month